Salud financiera de hoja de balance de AnaptysBio
Salud financiera controles de criterios 5/6
AnaptysBio tiene un patrimonio de los accionistas total de $88.1M y una deuda total de $310.8M, lo que sitúa su ratio deuda-patrimonio en 352.8%. Sus activos y pasivos totales son $452.4M y $364.3M respectivamente.
Información clave
352.8%
Ratio deuda-patrimonio
US$310.81m
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$390.90m |
| Patrimonio | US$88.10m |
| Total pasivo | US$364.29m |
| Activos totales | US$452.39m |
Actualizaciones recientes sobre salud financiera
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22
Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16Recent updates
Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11AnaptysBio (NASDAQ:ANAB) Is In A Strong Position To Grow Its Business
Jul 28Upgrade: Analysts Just Made A Dazzling Increase To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 09AnaptysBio EPS beats by $0.03, beats on revenue
May 04Industry Analysts Just Made A Huge Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts
Mar 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 28Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth
Feb 10Why AnaptysBio's (NASDAQ:ANAB) CEO Pay Matters
Dec 19AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside
Nov 30AnaptysBio (ANAB) Investor Presentation - Slideshow
Nov 18Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($406.8M) de ANAB superan a sus pasivos a corto plazo ($37.4M).
Pasivo a largo plazo: Los activos a corto plazo de ANAB ($406.8M) superan a sus pasivos a largo plazo ($326.8M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ANAB tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de ANAB ha crecido de 1.6% a 352.8% en los últimos 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ANAB tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.
Pronóstico de cash runway: ANAB dispone de suficiente cash runway para 2.7 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 15.1% cada año.